$XBI $133 +5%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA +7% Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel. source
$MRNA +7% Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents. source
$MRNA +7% Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union. source
$ADMP +5% Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19. source
$RDHL +4% RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study. source
Pipeline Updates
$ATOS +30% Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021. source
$CYDY -4% Nature Communications Publishes Study of CytoDyn’s Leronlimab Preventing HIV Infection in Primates source
$VERU +3% Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting. source
$CGEM +2% Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML. source
$NOVN +6% Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health. source
$HRMY +0% Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting. source
$CALA +2% Final data from CAlithera Biosciences' Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting. source
$ALLK +2% Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002). source
$BLUE +3% bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies. source
$EXEL -2% Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021. source
$MBIO +2% Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia. source
$EQ +7% Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases. source
$MEIP +5% MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib. source
$AMRX +4% Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches. source
$DCTH +2% Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting. source
$SRRK +7% Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting. source
$TBIO +3% Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program. source
$PTGX +2% Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021. source
$AUPH +3% Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress. source
$MDWD +2% MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal. source
$GLSI -3% Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated. source
$SWTX +8% SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma. source
$MNOV +5% MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury. source
$SVA -6% Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference. source
$UTHR +0% United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia. source
$AZN -1% Calquence demonstrated fewer incidences of atrial fibrillation versus ibrutinib in previously treated patients with chronic lymphocytic leukaemia and sustained patient benefit at four years in the front-line setting. source
$IOVA +13% Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting. source
Posted by FS/DV